Introduction
============

The fragile X--associated tremor/ataxia syndrome (FXTAS) is an adult-onset, progressive neurodegenerative disorder that affects individuals with a premutation (between 55 and 200 CGG repeats) in the fragile X mental retardation 1 (*FMR1*) gene ([@B11]; [@B13]). Forty to seventy five percent of males and 16--20% of females with *FMR1* premutations develop FXTAS ([@B10]). Although the main clinical features of FXTAS are cerebellar gait ataxia and action tremor ([@B1]; [@B9]), a subset of FXTAS patients suffer from nigrostriatal dysfunction and parkinsonism ([@B4]; [@B2]; [@B17]). Diagnoses of parkinsonian syndromes are based on clinical criteria, in which a definite diagnosis is achieved by neuropathological assessment. Here, we report histological findings of a patient with a *FMR1* premutation, who had a severe dopamine deficiency, according to \[^123^I\] ioflupane SPECT, and showed clinical signs compatible to the progressive supranuclear palsy -- corticobasal syndrome variant (PSP-CBS) as we have previously reported ([@B17]).

Materials and Methods {#s1}
=====================

This report was made within the frame of a study approved by the local ethics committee; the patient and her relatives have signed informed consent. Tissue for microscopy was collected according to a standard protocol for neurodegenerative disorders and included cortical areas from all lobes of the cerebrum, hippocampus, basal ganglia, thalamus, mesencephalon, pons, medulla oblongata and cerebellum. Five micrometer thick paraffin sections from all regions were stained with haematoxylin-eosin, luxol fast blue and modified Bielschowsky silver staining. Immunostainings with antibodies against hyperphosphorylated tau (AT8; Thermo Scientific) were made on sections from different cortical regions, basal ganglia, mesencephalon, pons, and cerebellum. Sections from different cortical regions, hippocampus, basal ganglia and cerebellum were also stained with antibodies against ubiquitin (Merck Millipore, Burlington, MA, United States). Sections from hippocampus were stained with antibodies against FMRpolyglycine (FMRpolyG) (clone 9FM-1B7; Merck Millipore, Burlington, MA, United States). Antibodies against three repeat (3R) and four repeat (4R) tau (both from Merck Millipore, Burlington, MA, United States) were used on sections from the frontal lobe. Immunostainings were performed on five μm thick paraffin sections on superfrost slides in a Bond immunostainer.

Results
=======

Phenomenology and Clinical Investigations
-----------------------------------------

The patient who we have previously reported ([@B17]), was a female harboring 82 CGG repeats in the *FMR1* gene. Her past medical record included premature ovarian failure (POF), the age of onset for motor symptoms was 44, and total disease duration six years. The phenotype consisted of severe and fast progressing parkinsonism, cognitive decline, apraxia, tachyphemia, echolalia and supranuclear palsy. Cognitive domains related to language, executive functions, attention, and memory were progressively impaired. Her saccades became slow and had increased initiation latency. The patient became wheelchair-bound, incontinent and developed akinetic mutism, and dystonia. These symptoms were unresponsive to L-dopa treatment or inhibition of MAO B or choline esterase and were compatible to PSP-CBS. MRI revealed mild atrophy in the mesencephalon, cerebellum and cortex. \[^123^I\] ioflupane SPECT demonstrated a major loss of the dopamine transporter in the basal ganglia. FDG-PET showed bilateral hypometabolism in frontal cortical lobes. Neurofilament light chain in the cerebrospinal fluid was slightly elevated, but beta-amyloid, tau and phospho-tau levels were normal. The patient died during sleep and an autopsy was performed.

Neuropathological Examination
-----------------------------

The formaldehyde-fixed brain weighed 1120 g, of which the cerebellum weighed 120 g. The frontal gyri appeared to be somewhat smaller than expected, and the thickness of the cortex was slightly reduced in the frontal lobes. The ventricles were of ordinary size. The substantia nigra was pale but without focal lesions. Microscopically, there was a severe reduction in neuromelanin-containing neurons with astrogliosis in the substantia nigra (**Figure [1A](#F1){ref-type="fig"}**). There was only a mild loss of pigmented neurons within the locus ceruleus in pons. Prominent neuronal loss and astrogliosis was evident in the pallidum, subthalamic nucleus and tectum. Mild loss of Purkinje cells in the cerebellar cortex was found (**Figure [1B](#F1){ref-type="fig"}**). In some neurons, small ubiquitin-positive intranuclear inclusions were present in the frontal lobe cortex (**Figure [2A](#F2){ref-type="fig"}**) and hippocampus (**Figure [2B](#F2){ref-type="fig"}**) as well as in the basal ganglia. Intranuclear inclusions were detected in neurons of the molecular cell layer of the cerebellum (**Figure [2C](#F2){ref-type="fig"}**). **Figure [2B](#F2){ref-type="fig"}** also illustrates an ubiquitin-positive tufted astrocyte. Inclusions containing FMRpolyG were prevalent in neurons of the hippocampus, especially in the CA4 region (**Figures [3A,B](#F3){ref-type="fig"}**). Occasionally, astrocyte-like cells also contained FMRpolyG positive inclusions (**Figure [3A](#F3){ref-type="fig"}**; thin arrow). The tau pathology was widespread, and tufted astrocytes were present in cortical regions, especially in the frontal lobe (**Figure [4A](#F4){ref-type="fig"}**). The tau pathology was also evident in the basal ganglia and tectum (**Figure [4B](#F4){ref-type="fig"}**). Numerous oligodendroglial coiled bodies were seen in the white matter (**Figure [4C](#F4){ref-type="fig"}**). In both gray and white matter, there were several tau-positive thread structures (**Figures [4B,C](#F4){ref-type="fig"}**). Tau-immunopositive neurons were especially numerous in the pons, including the locus ceruleus (**Figure [4D](#F4){ref-type="fig"}**). On sections stained with antibodies against 3R or 4R tau, only 4R tau positivity was found in these structures. **Figure [4E](#F4){ref-type="fig"}** illustrates tufted astrocytes stained for 4R tau in frontal cortex.

![**(A,B)** Haematoxylin-eosin staining showing severe loss of neuromelanin-containing neurons in substantia nigra and marked astrogliosis **(A)**. Reduction in the number of Purkinje cells (arrows) in cerebellum **(B)**. Scale bars: 100 μm.](fgene-09-00317-g001){#F1}

![**(A--C)** Ubiquitin-positive intranuclear inclusions (black arrows) in neurons in frontal cortex **(A)**, hippocampus **(B)**, and cerebellum **(C)**. A red arrow in **(B)** indicates an ubiquitin-positive tufted astrocyte. Scale bars: 25 μm.](fgene-09-00317-g002){#F2}

![**(A,B)** FMRpolyG positive inclusions in neurons (thick arrows) and in astrocyte-like cell (thin arrow in panel **A**) in the CA4 region of the hippocampus. Scale bars: 25 μm.](fgene-09-00317-g003){#F3}

![Tau staining with the AT8 antibody, demonstrating phosphorylated tau. In frontal cortex **(A)** and tectum **(B)**, tufted astrocytes were frequently found. In the white matter, there were many oligodendroglial coiled bodies along with thread-like structures **(C)**. Several neurons in locus coeruleus showed dense tau staining **(D)**. 4R tau staining in tufted astrocytes in the frontal cortex was evident **(E)**. Scale bars: 25 μm.](fgene-09-00317-g004){#F4}

To compare tau and nuclear inclusion pathologies, tau positive tufted astrocytes and ubiquitin inclusions were counted in four ×20 objective microscopic fields of view. In frontal and temporal cortices, 65 and 44 tau-positive tufted astrocytes were found, respectively. In the same cortical regions, two and four ubiquitin-positive inclusions were detected, respectively. No tau immunoreactivity was seen in the cerebellar cortex whereas six ubiquitin-positive inclusions were detected in the molecular layer.

Discussion
==========

Tau-pathology, specifically 4R tau, was identified in tufted astrocytes, oligodendroglial coiled bodies, thread structures and neurons. Thus, the character and distribution of the pathological abnormalities in the present case correspond to PSP ([@B3]). To best of our knowledge, this is the first report presenting a typical PSP pathology in a *FMR1* premutation carrier. It is worth to mention that the patient's father fulfills not only the criteria for FXTAS, but also displays the hummingbird sign, a hallmark of PSP, as well as dopamine deficiency on DAT scan ([@B17]).

We also found intranuclear ubiquitin-positive inclusions in the cerebral and cerebellar cortex as well as in the hippocampus and basal ganglia, which were consistent with FXTAS pathology. The presence of intranuclear inclusions in neurons and astrocytes is the pathological hallmark of FXTAS ([@B8], [@B7]; [@B20]). The inclusions are, in most cases, single and found throughout the brain with the highest abundance in the hippocampus. The intranuclear inclusions contain ubiquitin, heat-shock proteins, RNA-binding protein hnRNP A2 and *FMR1* mRNA to a less degree ([@B12]). Recently, FMRpolyG was identified in ubiquitin-positive inclusions in a mouse model of FXTAS and brains of FXTAS patients (frontal cortex and hippocampus) and induced pluripotent cells generated from FXTAS patients ([@B21]; [@B18]). Accordingly, we found FMRpolyG-positive inclusions in the hippocampus. FMRpolyG is the result of repeat-associated non-ATG (RAN) translation phenomenon. RAN translation has been found in other nucleotide expansion disorders (e.g., spinocerebellar ataxia 8 and myotonic dystrophy type 1**)** ([@B22]). RAN translation generates toxic peptides, but what regulates this process is not completely understood. The sole expression of the FMRpolyG is toxic in cell cultures and in *Drosophila* but only translation of expanded CGG repeats into FMRpolyG causes motor abnormalities in mice ([@B18]). Full CGG expansion in *FMR1* leads to hypermethylation and silencing of this gene, while 2--8 fold elevation of *FMR1* mRNA levels in premutation carriers only slightly reduce the expression of the gene product. Other than RAN translation, RNA toxicity induced by sequestration of transcription factors is another major underlying mechanism of disease for FXTAS ([@B6]).

Dual pathology in FXTAS includes disparate neurological conditions, such as chronic fatigue syndrome, multiple sclerosis, inclusion body myositis and atypical parkinsonism among many others ([@B7]; [@B19]; [@B4]; [@B2]; [@B15]; [@B16]). Neuropathological evidence of comorbidity among *FMR1* premutation carriers is scarce. However, there were four cases reported to have Alzheimer's disease, one with dementia with Lewy bodies, and four with Parkinson's disease ([@B7]; [@B19]; [@B2]; summarized in **Table [1](#T1){ref-type="table"}**).

###### 

Summary of *FMR1* premutation carriers with pathologically-confirmed concomitant proteinopathy.

  Phenotype            Number of cases (sex)   Concomitant proteinopathy       Reference
  -------------------- ----------------------- ------------------------------- ------------
  FXTAS and dementia   4                       Alzheimer's disease (3)         [@B19]
                       (All female)            Dementia with Lewy bodies (1)   
  FXTAS                3                       Parkinson's disease             [@B7];
                       (2 males, 1 female)                                     [@B19]^∗^;
                                                                               [@B2]
  PSP                  1                       Parkinson's disease             [@B2]
                       (male)                                                  
  PSP                  1                       PSP                             This work
                       (female)                                                

∗

These authors reported also concomitant multiple sclerosis

.

Fragile X--associated tremor/ataxia syndrome and PSP are associated with a wide phenotypic variability and overlapping clinical features. Up to 42% of PSP patients suffer from some form of tremor ([@B5]). There is also a PSP subtype with predominant cerebellar ataxia ([@B14]). Vertical gaze palsy, proceeded by slowed vertical saccades, are typical signs for PSP. These eye movement abnormalities along with dysmetric saccades, transient endgaze nystagmus, and square wave jerks have been observed in FXTAS patients ([@B4]).

The clinical PSP cases reported in a FXTAS cohort in the United States await pathological confirmation ([@B4]). Moreover, larger studies are needed in order to assess whether the *FMR1* premutation and/or other epigenetic factors are related to predispose tauo- and synucleinopathies. If an association can be confirmed, then elucidating the underlying mechanism(s) for this comorbidity should be a priority in future research.

Concluding Remarks
==================

This is the first presentation of characteristic PSP pathology in a *FMR1* premutation carrier further emphasizing the occurrence of dual pathology in FXTAS cases.
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